Blood–brain barrier disruption in dementia: Nano‐solutions as new treatment options.
Saved in:
| Title: | Blood–brain barrier disruption in dementia: Nano‐solutions as new treatment options. |
|---|---|
| Authors: | Cooper, Ceinwyn G. (AUTHOR), Kafetzis, Konstantinos N. (AUTHOR), Patabendige, Adjanie (AUTHOR), Tagalakis, Aristides D. (AUTHOR) |
| Source: | European Journal of Neuroscience. Mar2024, Vol. 59 Issue 6, p1359-1385. 27p. |
| Subjects: | Blood-brain barrier, Dementia, Drug delivery systems, Neurological disorders, Drug carriers, Central nervous system, Nanosatellites |
| Abstract: | Candidate drugs targeting the central nervous system (CNS) demonstrate extremely low clinical success rates, with more than 98% of potential treatments being discontinued due to poor blood–brain barrier (BBB) permeability. Neurological conditions were shown to be the second leading cause of death globally in 2016, with the number of people currently affected by neurological disorders increasing rapidly. This increasing trend, along with an inability to develop BBB permeating drugs, is presenting a major hurdle in the treatment of CNS‐related disorders, like dementia. To overcome this, it is necessary to understand the structure and function of the BBB, including the transport of molecules across its interface in both healthy and pathological conditions. The use of CNS drug carriers is rapidly gaining popularity in CNS research due to their ability to target BBB transport systems. Further research and development of drug delivery vehicles could provide essential information that can be used to develop novel treatments for neurological conditions. This review discusses the BBB and its transport systems and evaluates the potential of using nanoparticle‐based delivery systems as drug carriers for CNS disease with a focus on dementia. [ABSTRACT FROM AUTHOR] |
| Copyright of European Journal of Neuroscience is the property of Wiley-Blackwell and its content may not be copied or emailed to multiple sites without the copyright holder's express written permission. Additionally, content may not be used with any artificial intelligence tools or machine learning technologies. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.) | |
| Database: | Psychology and Behavioral Sciences Collection |
|
Full text is not displayed to guests.
Login for full access.
|
|
| Abstract: | Candidate drugs targeting the central nervous system (CNS) demonstrate extremely low clinical success rates, with more than 98% of potential treatments being discontinued due to poor blood–brain barrier (BBB) permeability. Neurological conditions were shown to be the second leading cause of death globally in 2016, with the number of people currently affected by neurological disorders increasing rapidly. This increasing trend, along with an inability to develop BBB permeating drugs, is presenting a major hurdle in the treatment of CNS‐related disorders, like dementia. To overcome this, it is necessary to understand the structure and function of the BBB, including the transport of molecules across its interface in both healthy and pathological conditions. The use of CNS drug carriers is rapidly gaining popularity in CNS research due to their ability to target BBB transport systems. Further research and development of drug delivery vehicles could provide essential information that can be used to develop novel treatments for neurological conditions. This review discusses the BBB and its transport systems and evaluates the potential of using nanoparticle‐based delivery systems as drug carriers for CNS disease with a focus on dementia. [ABSTRACT FROM AUTHOR] |
|---|---|
| ISSN: | 0953816X |
| DOI: | 10.1111/ejn.16229 |
